The epidemiology of factor VIII inhibitors
- 10 November 2006
- journal article
- review article
- Published by Wiley in Haemophilia
- Vol. 12 (s6) , 23-29
Abstract
Risk factors for inhibitor development include specific factor VIII (FVIII) genotypes, a family history of inhibitor development amongst first-degree relatives, certain HLA haplotypes and non-caucasian ethnicity. Patients with major FVIII deletions or rearrangements have a higher risk of inhibitor development than those with small deletions or missense mutations. Studies of HLA-DR amongst northern European patients with the intron 22 inversion indicate that certain HLA haplotypes may also confer either increased or decreased inhibitor risk. However, although brothers of patients with inhibitor have a high risk of inhibitor development, concordance is not 100%, and other constitutional factors must also operate. Disputed risk factors for inhibitor development include early age at first FVIII exposure, the use of recombinant rather than plasma-derived FVIII and product switching. Two studies suggest that inhibitor risk is increased by very early FVIII exposure (P = 0.03), but this is disputed by a third study; larger studies addressing the question are ongoing. Studies investigating the relative inhibitor risk of plasma-derived vs. recombinant FVIII have been similarly inconclusive and will be reviewed. Other environmental or treatment variables such as concomitant infection or vaccination are suspected to influence inhibitor risk but have not yet been fully investigated.Keywords
This publication has 32 references indexed in Scilit:
- Haemophilia Inhibitor Genetics Study – evaluation of a model for studies of complex diseases using linkage and association methodsHaemophilia, 2005
- Inhibitor Development in Patients with Hemophilia A after Continuous Infusion of FVIII ConcentratesAnnals of the New York Academy of Sciences, 2005
- Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia AThrombosis and Haemostasis, 2005
- Inhibitor Development in Previously Untreated Patients with Hemophilia A: A Prospective Long-Term Follow-Up Comparing Plasma-Derived and Recombinant ProductsSeminars in Thrombosis and Hemostasis, 2002
- The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor developmentHaemophilia, 2001
- Oral immune tolerance induction to factor VIII via breast milk, a possibility?Haemophilia, 2000
- Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma‐derived factor VIII concentratesHaemophilia, 1999
- The incidence of factor VIII inhibitors in the United Kingdom, 1990‐93British Journal of Haematology, 1995
- Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcomeBritish Journal of Haematology, 1990
- Genetic predisposition to develop factor VIII antibody in classic hemophiliaClinical Immunology and Immunopathology, 1977